Open Access
Review
E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy
Zhonglin Hao1,3,*,Shuang Huang2
1
Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA30912, USA
2
Department of Biochemistry, Medical College of Georgia, Georgia Regents University, Augusta, GA30912, USA
3
Cancer Center, Medical College of Georgia, Georgia Regents University, Augusta, GA30912, USA
DOI: 10.2741/4320 Volume 20 Issue 3, pp.474-490
Published: 01 January 2015
*Corresponding Author(s):  
Zhonglin Hao
E-mail:  
zhao@gru.edu
Abstract

E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression are discussed.

Key words
Skp2,E3 Ubiquitin ligase,Oncogenesis,Inhibitor,Cancer therapy,Review
Share and Cite
Zhonglin Hao, Shuang Huang. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Frontiers in Bioscience-Landmark. 2015. 20(3); 474-490.